Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01123655 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Trial of Type II Collagen (CII) APL A12 in Rheumatoid Arthritis Patients
A Phase 1 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT01123655: Completed Phase 1 study, sponsored by VA Office of Research and Development.
NCT01123655 is a Phase 1 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01123655, a Phase 1 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This is a Phase I clinical trial to determine whether orally administered APL A12 at one or more doses is superior to placebo in effecting a 25% reduction in interferon (IFN) stimulation index in 1(II)-stimulated culture of peripheral blood mononuclear (PBMC) obtained from patients with Rheumatoid Arthritis (RA), which will be the primary outcome variable. In an effort to learn more about the mechanism of action of APL A12, the investigators will assess Th1/Th2/Th3 cytokine production in supernatants from 48h and 144h cultures of PBMC stimulated by 1(II) and by APL A12 above. The investigators will assess function of CD4+ CD25+ T regs to determine whether APL A12 improves their suppressive function. Flow cytometry combined with intracellular cytokine staining will be used in an effort to determine which T cell subset(s) is/are experiencing shifts in cytokine expression.
Interventions
- DRUG Placebo
- DRUG APLA12
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2009-10 |
| Est. Completion | 2015-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01123655
The ClinicalTrials.gov registry entry for NCT01123655 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01123655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01123655 about?
NCT01123655 is a clinical study titled "Phase 1 Trial of Type II Collagen (CII) APL A12 in Rheumatoid Arthritis Patients". This is a Phase I clinical trial to determine whether orally administered APL A12 at one or more doses is superior to placebo in effecting a 25% reduction in interferon (IFN) stimulation index in 1(II)-stimulated culture of peripheral blood mononuclear (PBMC) obtained from patients with Rheumatoid A...
What is the current status of trial NCT01123655?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2009-10. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01123655?
The interventions under investigation include: Placebo (DRUG), APLA12 (DRUG).
Who is sponsoring clinical trial NCT01123655?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.